Pharmacokinetics of intranasal crushed oxycontin and intravenous oxycodone in nondependent prescription opioid abusers

Journal of Clinical Pharmacology

Volumn 52, Issue 4, 2012, Pages 600-606

  Lofwall, M R ^a   Moody, D E ^b   Fang, W B ^b   Nuzzo, P A ^a   Walsh, S L ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYCODONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; MALE; OPIATE ADDICTION;

ADMINISTRATION, INTRANASAL; ADULT; BIOLOGICAL AVAILABILITY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; NARCOTICS; OPIOID-RELATED DISORDERS; OXYCODONE; TABLETS; YOUNG ADULT;

EID: 84859033253     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011401620     Document Type: Article

References (31)

1. Office of Applied Studies. Results from the 2008 National Survey on Drug Use and Health (NSDUH): National Findings. Substance Abuse and Mental Health Service Administration NSDUH Series H-36 SMA 09-4434. Rockville, MD: Office of Applied Studies; 2009.
2. Lofwall MR, Schuster A, Strain EC. Changing profile of abused substances by older persons entering treatment. J Nerv Ment Dis. 2008;196:898-905.
3. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf. 2006;15:618-627. (Pubitemid 44404658)
4. Sung HE, Richter L, Vaughan R, Johnson PB, Thom B. Nonmedical use of prescription opioids among teenagers in the United States: trends and correlates. J Adolesc Health. 2005;37: 44-51. (Pubitemid 40826518)
5. Overdose deaths involving prescription opioids among Medicaid enrollees-Washington, 2004-2007. MMWR Morb Mortal Wkly Rep. 2009;58:1171-1175.
6. Paulozzi LJ, Ryan GW. Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med. 2006;31:506-511. (Pubitemid 44880582)
7. Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, Sannerud C. College onProblems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend. 2003;69:215-232. (Pubitemid 36293934)
8. Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health. 2009;99:221-227.
9. U.S. General Accounting Office (GAO) Report to Congressional Requesters. Prescription Drugs: OxyContin Abuse and Diversion and Efforts to Address the Problem. GAO 04-110. 1-57. Washington D.C.: United States Government General Accounting Office 2003.
10. Benziger DP, Kaiko RF, Miotto JB, Fitzmartin RD, Reder RF, Chasin M. Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution. J Pharm Sci. 1996;85:407-410. (Pubitemid 26106236)
11. Benziger DP, Miotto J, Grandy RP, Thomas GB, Swanton RE, Fitzmartin RD. A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone. J Pain Symptom Manage. 1997;13: 75-82.
12. Poyhia R, Seppala T, Olkkola KT, Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol. 1992;33:617-621.
13. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006;79:461-479.
14. Beaver WT, Wallenstein SL, Houde RW, Rogers A. Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer. J Clin Pharmacol. 1977;17:186-198. (Pubitemid 8071312)
15. FDA Anesthetic and Life Support Drugs and Drug Safety Risk Management Advisory Committee Meeting on May 5, 2008. Summary of Drug Abuse "Rates" in the United States; presentation by Catherine Dormitzer, Division of Epidemiology and Sales distribution data (IMS Health) Year 2007; presentation by Kendra Worthy and Laura Governale. http://www.fda.gov/ohrms/ dockets/ac/08/ slides/2008-4356s1-00-index.htm. Accessed October 13, 2010.
16. United States Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episode Data Set-Admissions (TEDSA), 2008 [computer file]. ICPSR27241-v2. Ann Arbor, MI: Interuniversity Consortium for Political and Social Research [distributor]; 2010. doi:10.3886/ICPSR27241. Electronic file accessed October 13, 2010.
17. Fang WB, Moody DE. Determination of oxycodone and metabolites by high performance liquid chromatography-electrospray ionization-tandem mass spectrometry. Paper presented at: the Society of Forensic Toxicologists Annual Meeting, October 15-19, 2007, Durham, NC; 2007.
18. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther. 1998;64:603-611. (Pubitemid 29011380)
19. Poyhia R, Olkkola KT, Seppala T, Kalso E. The pharmacokinetics of oxycodone after intravenous injection in adults. Br J Clin Pharmacol. 1991;32:516-518.
20. Baldacci A, Caslavska J, Wey AB, Thormann W. Identification of new oxycodone metabolites in human urine by capillary electrophoresis-multiple-stage ion-trap mass spectrometry. J Chromatogr A. 2004;1051:273-282. (Pubitemid 39298854)
21. Shelley K, Paech MJ. The clinical applications of intranasal opioids. Curr Drug Deliv. 2008;5:55-58.
22. Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv Drug Deliv Rev. 2005;57:1640-1665. (Pubitemid 41443473)
23. Takala A, Kaasalainen V, Seppala T, Kalso E, Olkkola KT. Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. Acta Anaesthesiol Scand. 1997;41: 309-312. (Pubitemid 27084661)
24. Matsuyama T, Morita T, Horikiri Y, Yamahara H, Yoshino H. Influence of fillers in powder formulations containing N-acetyl- L-cysteine on nasal peptide absorption. J Control Release. 2007;120:88-94. (Pubitemid 46874623)
25. Schipper NG, Romeijn SG, Verhoef JC, Merkus FW. Nasal insulin delivery with dimethyl-beta-cyclodextrin as an absorption enhancer in rabbits: powder more effective than liquid formulations. Pharm Res. 1993;10:682-686. (Pubitemid 23152312)
26. Ugwoke MI, Exaud S, Van Den Mooter G, Verbeke N, Kinget R. Bioavailability of apomorphine following intranasal administration of mucoadhesive drug delivery systems in rabbits. Eur J Pharm Sci. 1999;9:213-219. (Pubitemid 30012078)
27. Waller BF, Brownlee WJ, Roberts WC. Self-induced pulmonary granulomatosis: aconsequence of intravenous injection of drugs intended for oral use. Chest. 1980;78:90-94.
28. Greene D. Total necrosis of the intranasal structures and soft palate as a result of nasal inhalation of crushed OxyContin. Ear Nose Throat J. 2005;84:512, 514, 516.
29. Jewers WM, Rawal YB, Allen CM, et al. Palatal perforation associated with intranasal prescription narcotic abuse. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99:594-597. (Pubitemid 40522495)
30. Yewell J, Haydon R, Archer S, Manaligod JM. Complications of intranasal prescription narcotic abuse. Ann Otol Rhinol Laryngol. 2002;111:174-177. (Pubitemid 34131067)
31. Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008;98:181-202.